Oncología Traslacional
ONCTRAS
![Foto de Oncología Traslacional](/img/uploaded/8edbe5178cdb32cce4e7d9c57e11add8.jpg)
![Foto de Ohio State University](/img/noimage_org.png)
Ohio State University
Columbus, Estados UnidosPublicaciones en colaboración con investigadores/as de Ohio State University (6)
2023
2022
-
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Therapeutic Advances in Medical Oncology, Vol. 14
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
-
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385
2019
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402